Metabolix, Inc.  

(Public, NASDAQ:MBLX)   Watch this stock  
Find more results for MBLX
May 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 0.25 - 1.51
Open     -
Vol / Avg. 0.00/93,701.00
Mkt cap 103.01M
P/E     -
Div/yield     -
EPS -0.29
Shares 135.54M
Beta 1.30
Inst. own 19%
Aug 4, 2015
Q2 2015 Metabolix Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
May 13, 2015
Q1 2015 Metabolix Inc Earnings Call - Webcast
May 13, 2015
Q1 2015 Metabolix Inc Earnings Release
Mar 19, 2015
Q4 2014 Metabolix Inc Earnings Call - Webcast
Mar 19, 2015
Q4 2014 Metabolix Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -905.89% -956.00%
Operating margin -903.88% -958.18%
EBITD margin - -940.07%
Return on average assets -117.76% -107.34%
Return on average equity -145.90% -136.59%
Employees 68 -
CDP Score - -


21 Erie St
CAMBRIDGE, MA 02139-4260
United States - Map
+1-617-5831700 (Phone)
+1-617-5831768 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Metabolix, Inc., is a bioscience company focused on delivering sustainable solutions to the plastics and chemicals industries. It has focused on a family of biopolymers found in nature called polyhydroxyalkanoates (PHAs), which occur naturally in living organisms and are chemically similar to polyesters. It has demonstrated the production of PHAs at industrial scale to produce PHA biopolymers and PHA precursors to biobased industrial chemicals. The Company has also demonstrated the production of polyhydroxybutyrate (PHB), a subclass of PHAs, in agriculturally non-food crops. For the Company’s second platform, it is developing C4 and C3 chemicals from biobased sources, as opposed to the fossil fuels that are used to produce industrial chemicals. Its process for creating biobased industrial C4 and C3 chemicals involves engineering metabolic pathways into microbes that, in a fermentation process, produce specific PHA structures that serve as precursors for these chemicals.

Officers and directors

Robert L. Van Nostrand Chairman of the Board, Independent Director
Age: 58
Bio & Compensation  - Reuters
Joseph H. Shaulson President, Chief Executive Officer, Director
Age: 49
Bio & Compensation  - Reuters
Johan van Walsem Chief Operating Officer
Age: 52
Bio & Compensation  - Reuters
Charles B. Haaser Chief Accounting Officer
Age: 59
Bio & Compensation  - Reuters
Oliver P. Peoples Ph.D. Chief Scientific Officer, Director
Age: 57
Bio & Compensation  - Reuters
Lynne H. Brum Vice President - Marketing and Corporate Communications
Age: 51
Bio & Compensation  - Reuters
Sarah P. Cecil General Counsel, Secretary
Age: 63
Bio & Compensation  - Reuters
Peter N. Kellogg Independent Director
Age: 59
Bio & Compensation  - Reuters
Celeste B. Mastin Independent Director
Age: 46
Bio & Compensation  - Reuters
Anthony J. Sinskey Ph.D. Independent Director
Age: 75
Bio & Compensation  - Reuters